Heron Therapeutics, Inc.
HRTX
Price:
$1.07
Market Cap:
$162.74M
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor...[Read more]
Industry
Biotechnology
IPO Date
1987-08-26
Stock Exchange
NASDAQ
Ticker
HRTX
PE Ratio
[-6.69]
ROE
[76.79%]
Current Ratio
[2.28]
Dividend Yield
[0%]
Enterprise Value
[315.25M]
Dividend History
The ROE as of November 2024 (TTM) for Heron Therapeutics, Inc. (HRTX) is 76.79%
According to Heron Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 76.79%. This represents a change of 296.92% compared to the average of 19.35% of the last 4 quarters.
Heron Therapeutics, Inc. (HRTX) Historical ROE (quarterly & annually)
How has HRTX ROE performed in the past?
The mean historical ROE of Heron Therapeutics, Inc. over the last ten years is -67.98%. The current 76.79% ROE has changed -212.96% with respect to the historical average. Over the past ten years (40 quarters), HRTX's ROE was at its highest in in the June 2022 quarter at 290.85%. The ROE was at its lowest in in the September 2016 quarter at -271.30%.
Average
-67.98%
Median
-88.76%
Minimum
-991.13%
Maximum
814.75%
Heron Therapeutics, Inc. (HRTX) ROE by Quarter and Year
Discovering the peaks and valleys of Heron Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 253.22%
Maximum Annual ROE = 814.75%
Minimum Annual Increase = -1086.06%
Minimum Annual ROE = -991.13%
| Year | ROE | Change |
|---|---|---|
| 2023 | 325.43% | -132.83% |
| 2022 | -991.13% | 253.22% |
| 2021 | -280.60% | 195.68% |
| 2020 | -94.90% | 87.18% |
| 2019 | -50.70% | 4.94% |
| 2018 | -48.31% | -67.92% |
| 2017 | -150.59% | -118.48% |
| 2016 | 814.75% | -1086.06% |
| 2015 | -82.63% | -31.77% |
| 2014 | -121.10% | 51.03% |
Heron Therapeutics, Inc. (HRTX) Average ROE
How has HRTX ROE performed in the past?
The current ROE of Heron Therapeutics, Inc. (HRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-315.43%
5-year avg
-218.38%
10-year avg
-67.98%
Heron Therapeutics, Inc. (HRTX) ROE vs. Peers
How is HRTX’s ROE compared to its peers?
Heron Therapeutics, Inc.’s ROE is greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), less than Eledon Pharmaceuticals, Inc. (21.51%),
| Company | ROE | Market cap |
|---|---|---|
| -69.11% | $575.61M | |
| -32.76% | $491.80M | |
| -139.57% | $78.19M | |
| -88.42% | $180.51M | |
| -49.25% | $20.76M | |
| -32.51% | $57.64M | |
| -32.99% | $142.39M | |
| -22.40% | $1.38B | |
| 21.51% | $239.55M |
Build a custom stock screener for Heron Therapeutics, Inc. (HRTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Heron Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Heron Therapeutics, Inc. (HRTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Heron Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Heron Therapeutics, Inc.'s ROE?
How is the ROE calculated for Heron Therapeutics, Inc. (HRTX)?
What is the highest ROE for Heron Therapeutics, Inc. (HRTX)?
What is the 3-year average ROE for Heron Therapeutics, Inc. (HRTX)?
What is the 5-year average ROE for Heron Therapeutics, Inc. (HRTX)?
How does the current ROE for Heron Therapeutics, Inc. (HRTX) compare to its historical average?